SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Absci Corporation Common Stock
ABSI
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Last trade$7.57
Day change+$0.09 (+1.20%)
Day range$7.35 – $7.77
Volume3,470,717
Market cap$1.29B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.29B
Price / earnings
—
Price / book
5.91×
Price / sales
868.96×
EV / sales
860.01×
EV / EBITDA
-10.65×
Profitability
Earnings per share
-$0.73
Return on assets
-52.46%
Return on equity
-57.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.64×
Quick ratio
9.64×
Cash ratio
0.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$112.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABSI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$304K
$318K
$215K
$650K
$378K
$593K
$1.18M
$665K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$304K
$318K
$215K
$650K
$378K
$593K
$1.18M
$665K
Selling, general and administrative
$9.04M
$9.16M
$9.06M
$8.62M
$8.44M
$8.53M
$9.47M
$8.83M
Research and development
$23.57M
$22.62M
$19.28M
$25.35M
$19.25M
$20.46M
$16.36M
$18.38M
Total operating expenses
$35.3M
$34.48M
$31.06M
$31.69M
$30.53M
$31.99M
$28.91M
$30.44M
Operating income
-$34.99M
-$34.16M
-$30.85M
-$31.04M
-$30.15M
-$31.39M
-$27.73M
-$29.77M
Interest expense
-$2K
-$2K
-$18K
-$29K
-$45K
-$56K
-$79K
-$109K
Income before taxes
-$33.28M
-$33.17M
-$29.58M
-$29.72M
-$28.6M
-$30.44M
-$26.35M
-$28.96M
Income taxes
$18K
$40K
$18K
-$162K
$104K
$131K
-$4K
$21K
Net income
-$33.3M
-$33.21M
-$29.6M
-$29.56M
-$28.71M
-$30.57M
-$26.35M
-$28.98M
Net income attributable to common shareholders
-$33.3M
-$33.21M
-$29.6M
-$29.56M
-$28.71M
-$30.57M
-$26.35M
-$28.98M
EBITDA
-$32.31M
-$31.46M
-$28.12M
-$28.21M
-$27.31M
-$28.39M
-$24.66M
-$26.54M
Basic earnings per share
-$0.19
-$0.21
-$0.19
-$0.20
-$0.20
-$0.24
-$0.21
-$0.25
Diluted earnings per share
-$0.19
-$0.21
-$0.19
-$0.20
-$0.20
-$0.24
-$0.21
-$0.25
Recent news
Company coverage with links to the original publishers.
Absci Corporation (ABSI) reported a quarterly loss of $0.17 per share, missing the consensus estimate of $0.15 loss by 13.33%. Revenue came in at $0.3 million, significantly missing estimates by 88.43%. The company has failed to beat consensus estimates for four consecutive quarters. Despite a 190% year-to-date gain, ABSI received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
A comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.
AMD disclosed a $6.5 million stake in Marvell Technology through its latest 13F filing, with the position showing an estimated unrealized gain of approximately $4.3 million as Marvell shares have risen about 66% from AMD's implied entry price. The investment reflects AMD's exposure to AI infrastructure and data center semiconductor opportunities. AMD also holds positions in Absci Corp, Sanmina Corp, and Xanadu Quantum Technologies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.